MICROSOFT CORP Quarterly Goodwill in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
Summary
Microsoft Corp quarterly Goodwill history and growth rate from Q1 2010 to Q3 2024.
  • Microsoft Corp Goodwill for the quarter ending September 30, 2024 was $119B, a 76.1% increase year-over-year.
Goodwill, Quarterly (USD)
Goodwill, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $119B +$51.6B +76.1% Sep 30, 2024 10-Q 2024-10-30
Q2 2024 $119B +$51.3B +75.6% Jun 30, 2024 10-Q 2024-10-30
Q1 2024 $119B +$51.2B +75.4% Mar 31, 2024 10-Q 2024-04-25
Q4 2023 $119B +$51B +75.1% Dec 31, 2023 10-Q 2024-01-30
Q3 2023 $67.8B +$331M +0.49% Sep 30, 2023 10-Q 2023-10-24
Q2 2023 $67.9B +$362M +0.54% Jun 30, 2023 10-K 2024-07-30
Q1 2023 $67.9B +$569M +0.85% Mar 31, 2023 10-Q 2023-04-25
Q4 2022 $67.9B +$17B +33.4% Dec 31, 2022 10-Q 2023-01-24
Q3 2022 $67.5B +$17B +33.7% Sep 30, 2022 10-Q 2022-10-25
Q2 2022 $67.5B +$17.8B +35.8% Jun 30, 2022 10-K 2024-07-30
Q1 2022 $67.4B +$17.7B +35.6% Mar 31, 2022 10-Q 2022-04-26
Q4 2021 $50.9B +$6.7B +15.2% Dec 31, 2021 10-Q 2022-01-25
Q3 2021 $50.5B +$6.57B +15% Sep 30, 2021 10-Q 2021-10-26
Q2 2021 $49.7B +$6.36B +14.7% Jun 30, 2021 10-K 2023-07-27
Q1 2021 $49.7B +$7.63B +18.1% Mar 31, 2021 10-Q 2021-04-27
Q4 2020 $44.2B +$1.97B +4.67% Dec 31, 2020 10-Q 2021-01-26
Q3 2020 $43.9B +$1.78B +4.22% Sep 30, 2020 10-Q 2020-10-27
Q2 2020 $43.4B +$1.33B +3.15% Jun 30, 2020 10-K 2022-07-28
Q1 2020 $42.1B +$203M +0.49% Mar 31, 2020 10-Q 2020-04-29
Q4 2019 $42.2B +$671M +1.61% Dec 31, 2019 10-Q 2020-01-29
Q3 2019 $42.1B +$6.26B +17.5% Sep 30, 2019 10-Q 2019-10-23
Q2 2019 $42B +$6.34B +17.8% Jun 30, 2019 10-K 2021-07-29
Q1 2019 $41.9B +$6.28B +17.6% Mar 31, 2019 10-Q 2019-04-24
Q4 2018 $41.6B +$6.22B +17.6% Dec 31, 2018 10-Q 2019-01-30
Q3 2018 $35.9B +$466M +1.32% Sep 30, 2018 10-Q 2018-10-24
Q2 2018 $35.7B +$561M +1.6% Jun 30, 2018 10-K 2020-07-31
Q1 2018 $35.6B +$914M +2.64% Mar 31, 2018 10-Q 2018-04-26
Q4 2017 $35.4B +$831M +2.41% Dec 31, 2017 10-Q 2018-01-31
Q3 2017 $35.4B +$17.5B +97.6% Sep 30, 2017 10-Q 2017-10-26
Q2 2017 $35.1B +$17.3B +96.5% Jun 30, 2017 10-K 2019-08-01
Q1 2017 $34.7B +$16.7B +93.2% Mar 31, 2017 10-Q 2017-04-27
Q4 2016 $34.5B +$17.1B +98% Dec 31, 2016 10-Q 2017-01-26
Q3 2016 $17.9B +$765M +4.46% Sep 30, 2016 10-Q 2016-10-20
Q2 2016 $17.9B +$933M +5.51% Jun 30, 2016 10-K 2018-08-03
Q1 2016 $17.9B -$3.78B -17.4% Mar 31, 2016 10-Q 2016-04-21
Q4 2015 $17.4B -$4.42B -20.2% Dec 31, 2015 10-Q 2016-01-28
Q3 2015 $17.1B -$2.94B -14.6% Sep 30, 2015 10-Q 2015-10-22
Q2 2015 $16.9B -$3.19B -15.8% Jun 30, 2015 10-K 2017-08-02
Q1 2015 $21.7B +$6.98B +47.3% Mar 31, 2015 10-Q 2015-04-23
Q4 2014 $21.9B +$7.18B +48.9% Dec 31, 2014 10-Q 2015-01-26
Q3 2014 $20.1B +$5.41B +36.9% Sep 30, 2014 10-Q 2014-10-23
Q2 2014 $20.1B +$5.47B +37.3% Jun 30, 2014 10-K 2016-07-28
Q1 2014 $14.8B +$69M +0.47% Mar 31, 2014 10-Q 2014-04-24
Q4 2013 $14.7B -$47M -0.32% Dec 31, 2013 10-Q 2014-04-24
Q3 2013 $14.7B +$201M +1.39% Sep 30, 2013 10-Q 2014-01-23
Q2 2013 $14.7B +$1.2B +8.94% Jun 30, 2013 8-K 2015-10-27
Q1 2013 $14.7B -$5.02B -25.5% Mar 31, 2013 10-Q 2013-04-18
Q4 2012 $14.7B -$4.94B -25.1% Dec 31, 2012 10-Q 2013-04-18
Q3 2012 $14.5B +$1.93B +15.4% Sep 30, 2012 10-Q 2013-01-24
Q2 2012 $13.5B +$871M +6.92% Jun 30, 2012 10-K 2014-07-31
Q1 2012 $19.7B +$7.14B +56.9% Mar 31, 2012 10-Q 2012-04-19
Q4 2011 $19.7B +$7.17B +57.3% Dec 31, 2011 10-Q 2012-04-19
Q3 2011 $12.5B +$66M +0.53% Sep 30, 2011 10-Q/A 2012-01-27
Q2 2011 $12.6B +$187M +1.51% Jun 30, 2011 8-K 2013-11-26
Q1 2011 $12.6B +$91M +0.73% Mar 31, 2011 10-Q 2011-04-28
Q4 2010 $12.5B Dec 31, 2010 10-Q 2011-04-28
Q3 2010 $12.5B Sep 30, 2010 10-Q 2011-01-27
Q2 2010 $12.4B Jun 30, 2010 10-K 2012-07-26
Q1 2010 $12.5B Mar 31, 2010 10-Q 2010-04-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.